Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALL

Noelle V. Frey, MD, discusses the challenges of balancing the promises of chimeric antigen receptor T-cell therapy with its side effects in patients with relapsed/refractory acute lymphocytic leukemia.

SHARE